Why There’s Improved Outlook for Myeloma Patients

Print icon
By Dr. Peter Byeff

The prognosis for multiple myeloma is gradually improving as a result of new and improved therapies.

Multiple myeloma, which causes cancer cells to accumulate in bone marrow, can affect people of all ages, although the average age of onset is the sixth decade of life. New treatments including high-dose chemotherapy with stem cell support for appropriate patients, drugs in the classes of proteasome inhibitors, IMiDs (Immunomodulatory imide drugs) and other monoclonal antibodies such as daratumumab as well as bisphosphonates, which help to decrease skeletal-related events, have had a very significant impact on quality of life and survival.  Nonetheless, survivors face a number of challenges.

Long-term toxicity from treatments include neuropathy due to several of the new classes of drugs. Although it is an uncommon side effect, bone injury of the jaw secondary to treatment with bisphosphonates, can create very significant toxicity, which requires additional therapy.  Survivors also often have altered immunity, which makes them susceptible to a variety of infections.  The altered immunity may be due to myeloma itself, which often is accompanied by severe background suppression of the normal immune system and is sometimes treated by immune infusions that are given monthly.  Additionally, decreased immune response may be secondary to high dose chemotherapy with stem cell support or to drugs such as steroids which are used to treat myeloma.

Bone health is another issue for myeloma survivors.  They often have osteoporosis and involved bone lesions that may fracture. They often continue to receive medications to help bone health for a prolonged period to decrease the risk of a skeletal-related event.  Continued monitoring of the skeletal system is necessary.

Survivors of myeloma not infrequently will have diminished kidney function that may have been caused by the myeloma protein or elevated calcium levels in the blood. They may require continued surveillance for this. Decreased renal function may cause chronic anemia and may require treatment with agents such as epoetin to maintain an adequate red blood count.

Long-term survivors of myeloma are at significant risk of developing myelodysplasia, a chronic condition of white blood cells that may transform into acute leukemia, or acute leukemia itself due to the combined effects of therapy.  Survivors need continual monitoring of their blood counts to assess for any blood cell abnormalities.

The need for ongoing monitoring and treatment with these new cadre of medications may provide significant economic challenges to survivors due to the costs of these therapies. The Hartford HealthCare Cancer Institute offers financial and psychosocial counseling to help support patients and families during their cancer journey.

Dr. Peter Byeff is a Hartford HealthCare oncologist.

For more information on the Hartford HealthCare Cancer Institute and multiple myeloma, click here.

What's New

Healthy Diet

Cancer Survivors: Find The Power of a Healthy Diet

By Diane Avino Dietitian Gray Cancer Center Hartford HealthCare Cancer Institute at Hartford Hospital Eating well is important during all stages of life, but it’s particularly important for cancer survivorship. Adequate nutrition is a crucial part of staying well through cancer treatments as well as promoting your long-term health. Eating...


As Cancer Treatment Evolves, a Focus on Reducing Side Effects

By Dr. Omar Eton Melanoma DMT Lead Hartford HealthCare Cancer Institute Over the past two decades, there has been great progress in understanding the relationship between cancer and the defenses a patient can muster against it. This led to a Nobel Prize for James P. Allison and Tasuku Honjo in...

Stomach Cancer

Stomach Cancer: Signs You Shouldn’t Ignore

By Dr. Bret Schipper Chief of Surgical Oncology The Hospital of Central Connecticut and MidState Medical Center Stomach, or gastric, cancer in the United States is somewhat rare, but it’s important to know the signs and symptoms. According to the American Cancer Society, about 27,500 cases of stomach cancer will...

Dr. Bret Schipper

Dr. Bret Schipper, New Surgical Oncology Chief, Starts Seeing Patients

The Hartford HealthCare Cancer Institute has announced the appointment of Dr. Bret Schipper as chief of surgical oncology at Hartford Hospital and director of oncologic surgery for the entire Cancer Institute. Dr. Schipper’s areas of interest include hepatobiliary surgery, both benign and malignant; minimally-invasive robotic surgery; soft tissue (melanoma/sarcoma) and gastric...

Senior man giving wife a kiss

Why ‘Hot Chemo’ Can Be More Effective Than IV Against Cancer

While traditional chemotherapy drips intravenously into the body to circulate and attack deadly cancer cells, a faster, a more effective way of helping people with some cancers is now available at the Hartford HealthCare Cancer Institute. Called Hyperthermic Intraperitoneal Chemotherapy (HIPEC), the treatment is designed for people with cancers of...

Pancreatic Cancer

Where a Radiation Oncologist Fits in Your Pancreatic Cancer Treatment

Treating hepatobiliary cancer involves getting the most powerful treatment directly to the source of the disease, which is where the skill of a radiation oncologist often comes in. Dr. Timothy Boyd, a radiation oncologist with Hartford Hospital and part of the Hartford HealthCare Cancer Institute’s team approach to treating pancreatic...


Targeted Chemo Treatments Promising for HPB Patients

Everyone knows the connection between chemotherapy and cancer. It’s treatment and disease. With pancreatic cancer, maybe more than in other cancers, chemotherapy constitutes an integral part of the treatment. Medical oncologists oversee the use of chemo and other systemic treatments in patients with cancer, according to Dr. Rawad Elias, a...